Pediatrix Therapeutics (Hangzhou) Ltd.

Main research purposes: To study the single oral administration of the test preparation (specification: 360 mg, developed by Youer Pharmaceutical R&D (Hangzhou) Co., Ltd. and produced by Hangzhou Minsheng Pharmaceutical Co., Ltd.) and the reference preparation deferasirox granules (trade name) in fasting and postprandial states. : JADENU® Sprinkle, strength: 360mg, licensed by Novartis Pharmaceuticals Corp, produced by CatalentGermany Schorndorf GmbH) pharmacokinetics in healthy subjects, to evaluate the bioequivalence of the two oral preparations in fasting and fed states. Secondary research purpose: To evaluate the safety and tolerability of healthy subjects after a single oral administration of deferasirox granules test preparation and reference preparation under fasting and postprandial conditions.